NCT02587260 - Clinical Trial References

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Citation(s)

Bonello L, Laine M, Kipson N, Mancini J, Helal O, Fromonot J, Gariboldi V, Condo J, Thuny F, Frere C, Camoin-Jau L, Paganelli F, Dignat-George F, Guieu R
Ticagrelor increases adenosine plasma concentration in patients with an acute coronary syndrome. J A
Cattaneo M, Schulz R, Nylander S
Adenosine-mediated effects of ticagrelor: evidence and potential clinical relevance. J Am Coll Cardiol. 2014 Jun 17;63(23):2503-9. doi: 10.1016/j.jacc.2014.03.031. Review.
Flammer AJ, Anderson T, Celermajer DS, Creager MA, Deanfield J, Ganz P, Hamburg NM, Lüscher TF, Shechter M, Taddei S, Vita JA, Lerman A
The assessment of endothelial function: from research into clinical practice. Circulation. 2012 Aug 7;126(6):753-67. d
Hochberg Y, Benjamini Y
More powerful procedures for multiple significance testing. Stat Med. 1990 Jul;9(7):811-8.
McCrea CE, Skulas-Ray AC, Chow M, West SG
Test-retest reliability of pulse amplitude tonometry measures of vascular endothelial function: implications for clinical trial design. Vasc Med. 2012 Feb;17(1):29-36. doi: 10.1177/1358863X11433188.
Torngren K, Ohman J, Salmi H, Larsson J, Erlinge D
Ticagrelor improves peripheral arterial function in patients with a previous acute coronary syndrome. Cardiology. 2013;124(4):252-8. doi: 10.1159/000347122.

Hunting for the Off-Target Properties of Ticagrelor on Endothelial Function and Other Circulating Biomarkers in Humans

Clinical trial NCT02587260 - References